IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	10/689,022
Applicant(s)	:	Frank Hallock Ebetino et al.
Filed	:	10/20/2003
Title	:	Melanocortin Receptor Ligands
TC/A.U.	:	1646
Examiner	:	
Conf. No.	:	4104
Docket No.	:	9071M
Customer No.	:	27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] **37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)**

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [X] **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [] **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle)* has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. [] **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).** This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) **(For use with applications filed prior to or on June 30, 2003.)** Copies of the cited documents are enclosed.

OR

[X] (2) **(For use with applications filed after June 30, 2003.)** In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed. These references were cited in International Search reports of 04/26/2004 and 09/21/2004.

OR

[] (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

[] (4) Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

[] (6) It is respectfully request that the Examiner consider and make of record the co-pending applications listed on the attached page.

[] Additional information is attached.

Signature
Richard S. Echler, Sr.
Typed or printed name
Registration No. 41,006
(513) 622-1973

Date: October 21, 2004
Customer No. 27752

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 3

COMPLETE IF KNOWN	
Application Number	10/689,022
Confirmation Number	4104
Filing Date	10/20/2003
First Named Inventor	Frank Hallock Ebetino et al.
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	9071M

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.[1]	DOCUMENT NUMBER Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-4,251,438	02/17/1981	Moon	
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.[1]	FOREIGN PATENT DOCUMENT Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T[6]
	2	WO 02/076947 A1	10/03/2002	Schering Corp.		
	3	WO 02/48124 A2	06/20/2002	F. Hoffmann-La Roche AG; Vernalis Research Limited		
	4	WO 02/059108 A1	08/01/2002	Eli Lilly and Co.		
	5	WO 02/059095 A1	08/01/2002	Eli Lilly and Co.		
	6	WO 01/05331 A1	01/25/2001	Biocompatibles Ltd.		
	7	WO 00/66558 A1	11/09/2000	Schering Corp.		
	8	WO 02/079194 A1	10/10/2002	Schering Corp.		
	9	WO 98/52929 A1	11/26/1998	Pfizer Inc.		
	10	WO 02/064576 A1	08/22/2002	CV Therapeutics Inc.		
	11	WO 98/05292 A2	02/12/1998	Schering Corp.		
	12	WO 96/31478 A1	10/10/1996	Schering Corp.		
	13	WO 03/009850 A1	02/06/2003	Amgen Inc.		
	14	WO 02/085925 A2	10/31/2002	Procter & Gamble Co.		
	15	WO 03/061660 A1	07/31/2003	Eli Lilly and Co.		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO-SB08
(Revised for P&G use 10/8/2003)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 3

COMPLETE IF KNOWN	
Application Number	10/689,022
Confirmation Number	4104
Filing Date	10/20/2003
First Named Inventor	Frank Hallock Ebetino et al.
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	9071M

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.[1]	DOCUMENT NUMBER Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.[1]	FOREIGN PATENT DOCUMENT Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T[6]
	16	WO 03/022835 A1	03/20/2003	Schering Corp.		
	17	WO 03/035627 A1	05/01/2003	Pfizer Products Inc.		
	18	EP 1 122242 A1	08/08/2001	Yamanouchi Pharmaceutical Co. Ltd.		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO-SB08
(Revised for P&G use 10/8/2003)

Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-03)
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/689,022
	Confirmation Number	4104
	Filing Date	10/20/2003
	First Named Inventor	Frank Hallock Ebetino et al.
	Group Art Unit	1646
	Examiner Name	
SHEET 3 of 3	Attorney Docket Number	9071M

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	19	ANONYMOUS, "Mechanism(s) of Formation of Acrylamide in Food: Background", INTERNET ARTICLE, (retrieved from the Internet: URL:http://www.jitsan.umd.edu/Acrylamide/WG1/WG1_Mech_BG_Paper.pdf on 04-03-2003); XP002237515, pp 1-23.	
	20	MOTTRAM, D.S. et al., "Acrylamide is formed in the Maillard reaction", Nature, 2002, pp. 448-449, Vol. 419.	
	21	STADLER, R.H. et al., "Acrylamide from Maillard reaction products,"Nature, 2002, pp. 449-450, Vol. 419.	
	22	YAYLAYAN, V.A. et al., "Why asparagine needs carbohydrates to generate acrylamide", J. of Agric. Food Chem., 2003, pp. 1753-1757, Vol. 51.	
	23	JACKSON, L., "Formation Of Acrylamide In Food", Food Advisory committee. Contaminants and Natural Toxicants Subcommittee Meeting, December 4-5, 2002, pp. 10-1.	
	24	ZYZAK, D.V. et al., "Acrylamide formation mechanism in heated food", J. Agric. Food Chem., 2003, pp. 4782-4787, Vol. 51, No. 16.	
	25	FRIEDMAN, M., "Chemistry, Biochemistry and Safety of Acrylamide. A Review", J. Agric. Food Chem., 2003, pp. 4504-4526, Vol. 51, No. 16.	
	26	ELMORE, J.S. et al., "Compilation of free amino acids data for various food raw materials, showing the relative contributions of asparagine, glutamine, aspartic acid and glutamic acid to the free amino acid composition", INTERNET ARTICLE, (retrieved from the Internet: URL:http://www.jitsan.umd.edu/presentations/acrylamide2002/wgl_aspargine_in_foods.pdf on 04-08-20034); XP002276621.	
	27	MOTTRAM D. et al., "Suggested Mechanism for the formation of acrylamide in foods", INTERNET ARTICLE, (retrieved from the Internet: URL:http://www.jitsan.umd.edu/presentations/acrylamide2002/wgl_Mottram_D.pdf on 04-08-20034); XP002276622.	
	28	FALBE, J. et al., "Roompp Lexikon Lebensmittelchemie, ASPARAGIN", pp. 76 (XP002268124).	
	29	YAMASHITA, T. et al., "Synthesis and opiate activity of pseudo-tetrapeptides containing chiral piperazin-2-one and piperazine derivatives", Chem. & Pharm. Bulletin, 1997, pp. 1940-1944, Vol. 45, No. 12.	
	30	MOON, M.W. et al., "Piperazinone Enkephalin analogs", Pept. Synth., Struct., Funct., Proc. Am. Pept. Symp., 7th, 1981, pp. 641-644, Editor(s): Rich, Daniel H.; Gross, Erhard., Publisher: Pierce Chem. Co., Rockford, ILL.	
	31	GROSZKOWSKI, S. et al., "Synthesis of 1,4-Di(pyrrolidineacyl)piperazines, of 1,1-Di(piperidineacyl)-2-methylpiperazines and their quaternary salts", Roczniki chemii, 1973, pp. 1277-1280, Vol. 47, No. 6.	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO-SB08
(Revised for P&G use 10/8/2003)